Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | PLA2G4B | P0C869 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.46 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.46 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7596495 | 0.94 | RARB (0.51) | L3MBTL1GAAMAPTPKMTP53 | |
| SCHEMBL3626122 | 0.92 | GAA (0.59) | L3MBTL1GAATP53TSHRPLA2G4B | |
| SCHEMBL31228620 | 0.92 | GAA (0.59) | L3MBTL1GAATP53TSHRPLA2G4B | |
| SCHEMBL1874960 | 0.92 | L3MBTL1 (0.50) | L3MBTL1GAAMAPTPKMTP53 | |
| SCHEMBL9615211 | 0.90 | GAA (0.66) | L3MBTL1GAATP53TSHRPLA2G4B | |
| SCHEMBL10954272 | 0.90 | MAPT (0.59) | L3MBTL1GAAMAPTPKMTP53 | |
| SCHEMBL162987 | 0.86 | TP53 (0.64) | L3MBTL1GAATP53TSHRPLA2G4B | |
| SCHEMBL12516203 | 0.86 | GAA (0.59) | L3MBTL1GAAMAPTPKMTP53 | |
| SCHEMBL7646498 | 0.85 | HTT (0.50) | L3MBTL1GAAMAPTPKMTP53 | |
| SCHEMBL3562863 | 0.85 | HTT (0.47) | L3MBTL1GAAMAPTPKMTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102070579-B | The preparation method of 2-normal-butyl-3-(4-replaces propoxy-benzoyl)-5-substituted-amino cumarone | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2016-03-09 | — | — | CN | claimed |
| CN-102070579-A | Method for preparing 2-n-butyl-3-(4-substituted-propoxybenzoyl)-5-substituted aminobenzofuran | SHANGHAI INST PHARM INDUSTRY | 2011-05-25 | — | — | CN | claimed |
| US-20230295134-A1 | USE OF PHENYLQUINOLINONE DERIVATIVE OR FLAVONOID DERIVATIVE FOR TREATING NEUROPATHIC PAIN | HANGZHOU BIO-SINCERITY PHARMA-TECH CO., LTD. (CN) | 2023-09-21 | — | — | US | disclosed |
| US-20230295134-A1 | USE OF PHENYLQUINOLINONE DERIVATIVE OR FLAVONOID DERIVATIVE FOR TREATING NEUROPATHIC PAIN | HANGZHOU BIO-SINCERITY PHARMA-TECH CO., LTD. (CN) | 2023-09-21 | — | — | US | disclosed |
| CN-115521277-A | Method for preparing benzofuran compound | 山东新时代药业有限公司 | 2022-12-27 | — | — | CN | disclosed |
| WO-2021072642-A1 | USE OF PHENYLQUINOLINONES AND FLAVONOID DERIVATIVES FOR TREATING NEUROPATHIC PAIN | 杭州百诚医药科技股份有限公司 | 2021-04-22 | — | — | WO | disclosed |
| CN-105399709-A | Preparation method of dronedarone hydrochloride key intermediate | BEIJING HUAXI LIANHE TECH DEV CO LTD | 2016-03-16 | — | — | CN | disclosed |
| CN-102070577-B | 2-normal-butyl-3-(4-replaces propoxy-benzoyl)-5-substituted-amino cumarone and application thereof | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2016-03-09 | — | — | CN | disclosed |
| CN-102070579-B | The preparation method of 2-normal-butyl-3-(4-replaces propoxy-benzoyl)-5-substituted-amino cumarone | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2016-03-09 | — | — | CN | disclosed |
| CN-102757444-B | There is the benzofuran compounds of nitric oxide donors character | NANJING XINNUOTHAI PHARMACEUTICAL CO., LTD. (CN) | 2016-02-10 | — | — | CN | disclosed |
| CN-102070581-B | The preparation of 2-normal-butyl-3-(4-(the amino propoxy-of 3-di-n-butyl) benzoyl)-5-aminobenzofur | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2015-11-25 | — | — | CN | disclosed |
| US-20080275046-A1 | Compounds Comprising an Oxazole or Thiazole Moiety, Processes for Making Them, and Their Uses | UCB PHARMA, S.A. (BE) | 2008-11-06 | — | — | US | disclosed |
| US-20080161331-A1 | Compounds Comprising an Oxazoline or Thiazoline Moiety, Processes for Making Them, and Their Uses | UCB PHARMA, S.A. (BE) | 2008-07-03 | — | — | US | disclosed |
| US-20080161331-A1 | Compounds Comprising an Oxazoline or Thiazoline Moiety, Processes for Making Them, and Their Uses | UCB PHARMA, S.A. (BE) | 2008-07-03 | — | — | US | disclosed |
| US-20080161331-A1 | Compounds Comprising an Oxazoline or Thiazoline Moiety, Processes for Making Them, and Their Uses | UCB PHARMA, S.A. (BE) | 2008-07-03 | — | — | US | disclosed |
| EP-1866294-A1 | COMPOUNDS COMPRISING AN OXAZOLINE OR THIAZOLINE MOIETY, PROCESSES FOR MAKING THEM, AND THEIR USES | UCB Pharma, S.A. (BE) | 2007-12-19 | — | — | EP | disclosed |
| EP-1866293-A1 | COMPOUNDS COMPRISING AN OXAZOLE OR THIAZOLE MOIETY, PROCESSES FOR MAKING THEM, AND THEIR USES | UCB Pharma, S.A. (BE) | 2007-12-19 | — | — | EP | disclosed |
| WO-2006103045-A1 | COMPOUNDS COMPRISING AN OXAZOLE OR THIAZOLE MOIETY, PROCESSES FOR MAKING THEM, AND THEIR USES | UCB PHARMA S.A. (BE) | 2006-10-05 | — | — | WO | disclosed |
| WO-2006103057-A1 | COMPOUNDS COMPRISING AN OXAZOLINE OR THIAZOLINE MOIETY, PROCESSES FOR MAKING THEM, AND THEIR USES | UCB PHARMA, S.A. (BE) | 2006-10-05 | — | — | WO | disclosed |
| US-5223510-A | ALKYLAMINOALKYL DERIVATIVES OF BENZOFURAN, BENZOTHIOPHENE, INDOLE AND INDOLIZINE, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | SANOFI (FR) | 1993-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161331-A1 | Compounds Comprising an Oxazoline or Thiazoline Moiety, Processes for Making Them, and Their Uses | NR1H3, NR1I3, NR1I2 | L3MBTL1 4282/4885GAA 4609/4885MAPT 4347/4885 |
| US-20230295134-A1 | USE OF PHENYLQUINOLINONE DERIVATIVE OR FLAVONOID DERIVATIVE FOR TREATING NEUROPATHIC PAIN | HRH4, HRH2, HRH1 | L3MBTL1 4344/4885GAA 1327/4885MAPT 675/4885 |
| US-20080275046-A1 | Compounds Comprising an Oxazole or Thiazole Moiety, Processes for Making Them, and Their Uses | OXER1, OXTR, OGFR | L3MBTL1 1094/4885GAA 3115/4885MAPT 4002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.